News coverage about Crispr Therapeutics (NASDAQ:CRSP) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Crispr Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.8963414507534 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Here’s Why CRISPR Therapeutics AG Gained as Much as 14% Today (msn.com)
- Crispr Therapeutics (CRSP) Given “Overweight” Rating at Piper Jaffray Companies (americanbankingnews.com)
- Crispr Therapeutics (CRSP) Receives “Buy” Rating from SunTrust Banks (americanbankingnews.com)
- CRISPR Therapeutics AG (CRSP) Is Standing to Counter Long-Term Compulsion – Stock News Stop (stockmarketstop.com)
- Hot Stock’s Trend Recap: CRISPR Therapeutics AG (NASDAQ: CRSP) – Alpha Beta Stock (alphabetastock.com)
CRSP has been the subject of a number of analyst reports. SunTrust Banks upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Piper Jaffray Companies restated a “buy” rating and issued a $22.75 price target (down previously from $39.00) on shares of Crispr Therapeutics in a research report on Wednesday, January 10th. BidaskClub upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. Oppenheimer reiterated a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, December 21st. Finally, Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a research report on Sunday, December 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $53.53.
In other Crispr Therapeutics news, major shareholder Aktiengesellschaft Bayer bought 527,472 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was purchased at an average price of $22.75 per share, for a total transaction of $11,999,988.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kurt Von Emster sold 37,754 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $26.76, for a total value of $1,010,297.04. The disclosure for this sale can be found here. Insiders have sold 298,850 shares of company stock valued at $7,545,365 in the last quarter. 39.98% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Crispr Therapeutics (CRSP) Stock Price” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://sportsperspectives.com/2018/03/12/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-crispr-therapeutics-crsp-stock-price.html.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.